Overview

Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy) conformal radiotherapy in moderate high-risk prostate cancer patients. Stratification will be performed by prognostic factors and by participating institution.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Treatments:
Androgens
Ascorbic Acid
Bicalutamide
Estrogens, Conjugated (USP)
Methyltestosterone